Limited coverage drugs – tinzaparin

Brand name

Dosage form

Strength

Innohep®

prefilled syringe

• 2,500 IU/0.25 mL
• 3,500 IU/0.35 mL
• 4,500 IU/0.45 mL
• 8,000 IU/0.4 mL
• 10,000 IU/0.5 mL
• 12,000 IU/0.6 mL
• 14,000 IU/0.7 mL
• 16,000 IU/0.8 mL
• 18,000 IU/0.9 mL

vial

• 10,000 IU/mL
• 20,000 IU/mL

For the treatment of:

• patients with acute deep vein thrombosis or pulmonary embolus who continue to receive care after leaving an acute care (hospital) setting. This treatment bridges the time gap to achieve therapeutic INR on oral anticoagulants

OR

up to 10 days’ supply

• patients with treatment failure on oral anticoagulant therapy (recurrence of one or more deep vein thromboses or pulmonary emboli in patients with therapeutic INR on oral anticoagulants)

OR

up to 3 months, then reassessed

• patients with cancer associated thrombosis

up to 6 months

For VTE prevention in patients:

• following elective total knee replacement surgery OR

• up to 14 days

• following elective total hip replacement surgery OR

• up to 35 days

• following orthopedic surgery for major trauma OR

• up to 10 days

• with lupus anticoagulant syndrome, antiphospholipid syndrome, or thrombophilia OR

• up to 3 months

• before, during or after pregnancy

• up to 4 weeks post-partum